Business Description
Corcept Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US2183521028
Share Class Description:
CORT: Ordinary SharesDescription
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 56.01 | |||||
| Equity-to-Asset | 0.82 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | 0.05 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 28.26 | |||||
| Beneish M-Score | -1.29 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 14.9 | |||||
| 3-Year EBITDA Growth Rate | -2.2 | |||||
| 3-Year EPS without NRI Growth Rate | 3.4 | |||||
| 3-Year FCF Growth Rate | -2.2 | |||||
| 3-Year Book Growth Rate | 3 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 55.75 | |||||
| Future 3-5Y Total Revenue Growth Rate | 30.7 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 70.27 | |||||
| 9-Day RSI | 66.6 | |||||
| 14-Day RSI | 65.81 | |||||
| 6-1 Month Momentum % | 71.8 | |||||
| 12-1 Month Momentum % | 87.1 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.7 | |||||
| Quick Ratio | 3.64 | |||||
| Cash Ratio | 3.01 | |||||
| Days Inventory | 289.18 | |||||
| Days Sales Outstanding | 29.13 | |||||
| Days Payable | 630.97 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 4 | |||||
| Shareholder Yield % | -0.04 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 98.44 | |||||
| Operating Margin % | 22.81 | |||||
| Net Margin % | 22.56 | |||||
| FCF Margin % | 23.01 | |||||
| ROE % | 25.77 | |||||
| ROA % | 21.04 | |||||
| ROIC % | 51.14 | |||||
| ROC (Joel Greenblatt) % | 4325.34 | |||||
| ROCE % | 25.42 | |||||
| Years of Profitability over Past 10-Year | 8 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 46.51 | |||||
| Forward PE Ratio | 33.53 | |||||
| PE Ratio without NRI | 46.51 | |||||
| Shiller PE Ratio | 72.35 | |||||
| Price-to-Owner-Earnings | 67.73 | |||||
| PEG Ratio | 8.61 | |||||
| PS Ratio | 10.41 | |||||
| PB Ratio | 9.61 | |||||
| Price-to-Tangible-Book | 9.61 | |||||
| Price-to-Free-Cash-Flow | 45.51 | |||||
| Price-to-Operating-Cash-Flow | 45.51 | |||||
| EV-to-EBIT | 40.21 | |||||
| EV-to-EBITDA | 39.89 | |||||
| EV-to-Revenue | 9.17 | |||||
| EV-to-Forward-Revenue | 7.15 | |||||
| EV-to-FCF | 39.85 | |||||
| Price-to-Projected-FCF | 2.5 | |||||
| Price-to-Median-PS-Value | 1.28 | |||||
| Price-to-Graham-Number | 4.46 | |||||
| Price-to-Net-Current-Asset-Value | 19.09 | |||||
| Price-to-Net-Cash | 26.16 | |||||
| Earnings Yield (Greenblatt) % | 2.49 | |||||
| FCF Yield % | 2.36 | |||||
| Forward Rate of Return (Yacktman) % | 4.43 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CORT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Corcept Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 628.555 | ||
| EPS (TTM) ($) | 1.26 | ||
| Beta | 0.72 | ||
| Volatility % | 67.31 | ||
| 14-Day RSI | 65.81 | ||
| 14-Day ATR ($) | 2.336673 | ||
| 20-Day SMA ($) | 54.97625 | ||
| 12-1 Month Momentum % | 87.1 | ||
| 52-Week Range ($) | 20.84 - 61.663 | ||
| Shares Outstanding (Mil) | 104.78 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Corcept Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Corcept Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Corcept Therapeutics Inc Frequently Asked Questions
What is Corcept Therapeutics Inc(CORT)'s stock price today?
The current price of CORT is $58.60. The 52 week high of CORT is $61.66 and 52 week low is $20.84.
When is next earnings date of Corcept Therapeutics Inc(CORT)?
The next earnings date of Corcept Therapeutics Inc(CORT) is 2025-02-14 Est..
Does Corcept Therapeutics Inc(CORT) pay dividends? If so, how much?
Corcept Therapeutics Inc(CORT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers